Ascentage Pharma Group International (NASDAQ:AAPG) Coverage Initiated at BTIG Research

Research analysts at BTIG Research assumed coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research report issued to clients and investors on Thursday, MarketBeat reports. The firm set a “buy” rating and a $48.00 price target on the stock. BTIG Research’s price objective suggests a potential upside of 96.48% from the company’s current price.

Several other research firms have also weighed in on AAPG. Oppenheimer started coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a report on Monday, November 24th. Finally, Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Trading Up 1.8%

Shares of AAPG opened at $24.43 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a 52-week low of $17.56 and a 52-week high of $48.45. The business’s fifty day moving average is $25.05 and its 200-day moving average is $31.18.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AAPG. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $96,000. ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International during the third quarter worth about $204,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International in the third quarter worth approximately $383,000. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International in the second quarter worth approximately $391,000. Finally, Tema Etfs LLC bought a new stake in Ascentage Pharma Group International in the second quarter valued at approximately $610,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.